Menu
Synergy in Action

2017 Autumn Conference includes Joint Day with ECNP

31 August – 02 September, 2017   //   Le Meridien Etoile, Paris, FR

Distinguished Poster Award Recipients:

Effect of High within Subject Variance at Research Sites on Placebo Response and Drug Placebo Separation in Acute Schizophrenia Trials – A Post Hoc Analysis (Kott)

Replication of a Statistical Method to Reduce Pseudospecificity and Enhance Understanding of Score Changes Among PANSS Factors (Mahableshwarkar)

All Poster PDFs and Abstracts are available at the end of the second day.

31 August 2017

Welcome Reception

1 September 2017
(Includes Joint Sessions with ECNP)

Welcome from the Presidents S Marder
slides 
slides
C Arango
slides 
slides
Beyond Efficacy: Hard Outcomes in Treatment Studies Chairs:
N Schooler
G Goodwin
  Introduction G Goodwin
slides 
slides
  Within-subject comparison as a tool to explore effectiveness in register studies M Landén
slides 
slides
  Relapse prevention studies: What happens after drop out? S Leucht
slides 
slides
  Industry Perspective: Risk characterization utilizing external data sources: A methodological consideration for clinical trials with high subject drop-out J Geier
slides 
slides
  Regulatory Comment/Panel Audience Discussion M Tome
Speakers
Clinician Reported Outcomes in Multinational CNS Trials: Practical Guidance on Translation and Cultural Adaptation Chairs:
A Kalali
E Vieta
  Introduction and background A Kalali
  The impact of language and culture on implementing multinational clinical trials M Vance
slides 
slides
  Cultural learnings implementing multinational clinical trials E Vieta
slides 
slides
  Guidance document – overview and highlights  E Pappadopulos
slides 
slides
Drug Development for Negative Symptoms in Schizophrenia: What Have We Learned?  What Can We Do Better? Chairs:
D Umbricht
C Arango 
  Welcome and introduction D Umbricht
  Negative symptoms: Prevalence, specificity, course and other characteristics M Weiser
slides 
slides
  Preclinical models of negative symptoms and their implications for clinical trials M Kas
slides 
slides
  Negative symptoms: Clinical assessments, biomarkers and the role of reward processing J Gold
slides 
slides
  Lessons learned in recent trials in negative symptoms D Umbricht
slides 
slides
  Conclusion and next steps J Lieberman
slides 
slides
  Panel discussion/Regulatory Comment Moderator:
J Lieberman
  Concluding remarks C Arango
  Joint meeting adjournment S Marder
C Arango
ISCTM Poster Session Poster PDFs and Abstracts

2 September 2017

 
Behavioral and Psychiatric Symptoms in Dementia (BPSD): A Way Forward? Chairs:
L Ereshefsky
L Pani
  Background, brief overview and session’s purpose L Ereshefsky
L Pani
  Segment 1- Agitation in Alzheimer’s Disease  
  Lessons learned – Part One – Agitation in Alzheimer’s Disease Progress in Trials Designs B Creese
slides 
slides
  Lessons learned – Part Two – Agitation in Alzheimer’s Disease Developing New Treatments P Rosenberg
slides 
slides
  Comments from Industry Perspective S Dube
slides 
slides
  Regulatory Viewpoints – Agitation in AD  V Mantua
slides 
slides
T Farchione
slides 
slides
  Panel – Audience discussion – Agitation in AD Facilitators:
J Rasmussen
J Bell
Agitation Panel
  Segment 2 – Apathy in Alzheimer’s Disease  
  Why focus on apathy? Diagnosis, symptoms assessment, methodology framework D Miller
slides 
slides
  Neuro-circuitry and implications for drug development: ADMET trials, and study designs for treatment of apathy

K Lanctot
slides 
slides

  Quantifiable assessments of motivational deficits and apathy in dementia – and beyond S Pollentier
slides 
slides
  Treatment of apathy in psychiatry and neurodegenerative disorders: Are positive valence systems of reward shared in common? Early drug development implications L Ereshefsky
slides 
slides
  Regulatory viewpoints – Apathy in AD V Mantua
slides
 slides
T Farchione

  Panel/Audience discussion – Apathy in AD Facilitators:
L Ereshefsky
S Pollentier
Apathy panel
  Concluding Discussant/Panel-audience discussion – Agitation and Apathy Discussant:
L Pani
slides 
slides
All Presenters
  Final comments L Pani
  Meeting Adjourns S Marder